Hematopoietic-derived GM-CSF is dispensable for the development of AMs in the neonatal lung.
(A–F) Analysis of P10 lungs isolated from Csf2fl and Vav1iCre/+;Csf2fl mice. (A) Flow cytometry analysis of the Thy1.2+tdTomato+ population, gated on CD45+ cells. (B) Flow cytometry analysis of the EpCAM+ tdTomato+ population, gated on CD45− cells. (C) Flow cytometry analysis of GM-CSF production in ILC2s (CD45+Lin−Thy1.2+ST2+) after restimulation with PMA/ionomycin (top row) or incubation with medium only (bottom row). (D) Percentage of GM-CSF+ ILC2s after restimulation or in the presence of medium only. (E) Flow cytometry analysis of CD11c+SiglecF+ AMs, gated on CD45+Ly-6G− cells. (F) Quantification of AMs. (G) Quantification of AMs in P10 lungs of Rag2+/+;Il2rg+/+ and Rag2−/−;Il2rg−/− mice. (H) Quantification of AMs (CD45+SiglecF+CD11c+) in P10 lungs of Mcpt8YFP-Cre;R26+/+ and Mcpt8YFP-Cre;R26DTA/+ mice. Mcpt8YFP-Cre/+ mice are indicated by circles, while Mcpt8YFP-Cre/YFP-Cre mice are indicated by triangles. (I) Representative IF pictures of tdTomato+ cells (red) and CD45+ cells (green) in P10 lungs of Csf2fl, Vav1iCre/+;Csf2fl, and Csf2Δ/Δ mice (scale bars 20 µm). (A–C, E, and I) Data are from one experiment representative of at least two independent experiments. (D and F–H) Data are pooled from two (D), four (F), or three (G and H) independent experiments. ns, P ≥ 0.05; ****, P < 0.0001.